ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia

Key Points

• To evaluate the efficacy and safety of 78 weeks of alirocumab treatment in individuals with heterozygous familial hypercholesterolaemia.
• Interventional trials (ODYSSEY FH I and FH II; ClinicalTrials.gov identifiers NCT01623115 and NCT01709500) with a 78-week follow-up period.
• Included a total cohort of 735 patients diagnosed with heterozygous familial hypercholesterolaemia.
• Alirocumab treatment was evaluated over a 78-week timeframe in 735 patients with heterozygous familial hypercholesterolaemia.
• Numerical effect sizes and per-arm primary endpoint event rates were not provided in the summary text.